Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance
Open accessThe DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index; 71 of the 195 sources its claims cite were checked for support.
Abstract
Adipose tissue (AT) represents a plastic organ that can undergo significant remodeling in response to metabolic demands. With its numerous checkpoints, the incretin system seems to play a significant role in controlling glucose homeostasis and energy balance. The importance of the incretin hormones, namely the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic peptide (GIP), in controlling the function of adipose cells has been brought to light by recent studies. Notably, a “paradigm shift” in reevaluating the role of the incretin system in AT as a potential target to treat obesity-linked metabolic disorders resulted from the demonstration that a disruption of the GIP and GLP-1 signaling axis in fat is associated with adiposity-induced insulin-resistance (IR) and/or type 2 diabetes mellitus (T2D). We will briefly discuss the (patho)physiological functions of GLP-1 and GIP signaling in AT in this review, emphasizing their potential impacts on lipid storage, adipogenesis, glucose metabolism and inflammation. We will also address the conundrum with the perturbation of the incretin axis in white or brown fat tissue and the emergence of metabolic disorders. In order to reduce or avoid adiposity-related metabolic complications, we will finally go over a potential scientific rationale for suggesting AT as a novel target for GLP-1 and GIP receptor agonists and co-agonists.
Overview
CoChat Summary
TL;DR
This narrative review argues that adipose tissue is a direct target of the incretin axis, proposing that disrupted GLP-1 and GIP signaling in fat contributes to obesity-linked insulin resistance and type 2 diabetes. It synthesizes receptor-expression, mechanistic, and clinical evidence to support repositioning adipose tissue as a therapeutic target for incretin-based drugs and co-agonists.
Key findings
- GLP-1 receptors are expressed in both mature adipocytes and the stromal vascular fraction of human adipose tissue; GLP-1R expression in visceral fat is up-regulated in morbid obesity with a high degree of insulin resistance, while subcutaneous expression does not differ by IR degree, suggesting a possible compensatory mechanism.
- GLP-1 has dose-dependent, opposing effects on adipocytes: lipogenic action predominates at picomolar concentrations and lipolytic action at nanomolar doses; GLP-1 also promotes pre-adipocyte differentiation, inhibits apoptosis, and increases insulin-dependent glucose uptake via GLUT4 up-regulation.
- GIP receptors are present on fat cells; GIP facilitates glucose uptake, lipoprotein lipase activity and lipogenesis, and GIP-R expression increases with adipocyte differentiation. GIP-R expression is down-regulated in subcutaneous adipose tissue of obese individuals and negatively associated with BMI, waist circumference, systolic blood pressure, glucose and TAG values.
- A meta-analysis of 10 trials found GLP-1 RA treatment reduced visceral adipose tissue by 11.2% versus 8.3% for subcutaneous adipose tissue in patients with T2D.
- Weight loss with GLP-1 RAs is more pronounced in females than males; women had 32% higher liraglutide exposure than men at similar weights, and GI adverse events (more common in females) are associated with greater weight reduction.
- Human studies of liraglutide (1.8 mg/day, 26 weeks) and exenatide found no significant reduction in supraclavicular brown adipose tissue fat fraction, and REE was reduced or unchanged.
Methods
- Narrative review; no primary data collection or systematic search protocol is described.
- Synthesizes preclinical (cell culture, rodent) and human evidence on GLP-1/GIP receptor expression and action in white, brown and beige adipose tissue, plus clinical trial and meta-analytic data on GLP-1 RA effects on fat depots, sex differences, and cancer risk.
- Includes discussion of incretin signaling mechanisms (cAMP/PKA/EPAC2, ERK-1/2, β-arrestin, Gαq/PKC pathways) and hepatic, skeletal muscle and adipose actions.
Limitations
- The paper states that molecular mechanisms of incretin action are "complex, cell-specific, and not fully understood," and that data on GLP-1 and GIP effects in skeletal muscle are "still scant" with mechanisms "basically unclear."
- The authors note that findings on GLP-1R expression in adipose tissue are pertinent only to individuals with morbid obesity and T2D and cannot be generalized to non-morbidly obese or overweight subjects with insulin resistance; GLP-1R expression in adipose tissue was not useful for predicting diabetes remission, IR improvement or weight loss after bariatric surgery.
- The authors state that conflicting findings on GIP actions in adipose tissue are at odds with recent clinical results and may reflect missing tools to evaluate long-term GIP-R stimulation effects; the paradoxical similar metabolic effects of GIP agonists and antagonists "remain to be resolved."
- Evident from the text: as a narrative review without a stated systematic search strategy, selection of cited evidence is not transparently reproducible.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
61 Valid · 9 Not valid · 88 Not checked · 34 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Currently, the literature provides conflicting evidence about a sexual dimorphism on the anti-hyperglicemic effect of GLP-1 RAs in subjects with T2D.”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 6. Expression and Activity of GLP-1 Receptors in Adipose Tissue > 6.2. Sex Differences in Response to GLP-1 RA Therapy in Type 2 Diabetes and Obesity: Prefential Effects in Subcutaneous vs. Visceral Fat Depot
What the sources say
- Disputedcites [85] Gallwitz, 2018, Effect of once-weekly dulaglutide on glycated haemoglobin (Hba1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c, Diabetes Obes. Metab. sourceExperimental — accuracy not yet measured
Our copy characterises the GLP‑1 RA sex-difference literature on glycaemic efficacy as concordant, not conflicting: the DISCUSSION states that the gender-independent HbA1c improvements 'are consistent with results observed in the subgroup analyses of exenatide twice daily, exenatide once weekly, and lixisenatide', that a liraglutide real-practice study 'also showed no differences in HbA1c reductions between women and men, consistent with our findings', and that no HbA1c difference was seen in Japanese dulaglutide patients. The Abstract Conclusions and the DISCUSSION opening likewise report significant glycaemic improvement 'irrespective of gender', with similar LS-mean HbA1c reductions in men and women at 6 and 12 months (RESULTS, HbA1c/FBG by gender). The only sex-specific signal the paper reports is in body weight (numerically greater loss in women, with a leptin-interaction hypothesis and a call for future investigation), which is not the anti-hyperglycaemic effect the claim describes; no passage in our copy says the evidence on glycaemic dimorphism is conflicting. (LLM, conf=0.70)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [86] Quan, 2016, Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus, J. Diabetes Its Complicat. source
- Partly supportedcites [87] Durden, 2016, Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States, J. Med. Econ. sourceExperimental — accuracy not yet measured
Our copy does address sexual dimorphism in the glycemic effect of a GLP-1 RA in T2D: the Predictors of glycemic control section (Table 4 discussion) reports females were more likely than males to achieve A1C ≤7% (OR = 1.75; p<0.05), and the Discussion notes an age-dependent gender effect, with younger women achieving higher rates of control. However, the paper never characterises the wider literature as conflicting or inconsistent on this point — it reports its own single-direction finding in 417 US commercially insured liraglutide initiators and does not review or contrast prior studies on sex differences with GLP-1 RAs. So the 'sexual dimorphism in anti-hyperglycemic effect of GLP-1 RAs in T2D' element is supported, but the attribution of 'conflicting evidence in the literature' is not made by this source. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, it has been suggested that the inhibition of new adipose cell formation is a trigger for the development of insulin resistance (IR), principally in the subcutaneous (sc) fat depots (i.e., abdominal and tight fat).”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 1. The Remodeling of Adipose Tissue
What the sources say
- Not checked yetcites [4] Danforth, 2000, Failure of adipocyte differentiation causes type II diabetes mellitus?, Nat. Genet. source
- Partly supportedcites [5] Sethi, 2010, Activatin’ human adipose progenitors in obesity, Diabetes sourceExperimental — accuracy not yet measured
Sethi's commentary does endorse the underlying idea: the opening section lays out the 'adipose tissue expandability hypothesis' (limit on safe triglyceride storage → ectopic fat → 'lipotoxicity and metabolic dysregulation of peripheral tissues', and 'similar metabolic consequences may also be predicted... when there is a paucity of adipose tissue'), and the section on adipose cellularity notes obese diabetics have 'fewer but larger adipocytes' with an inverse correlation between preadipocyte differentiation capacity and BMI (refs 5-7), while the summary states 'limitations in fat storage can lead to metabolic disorders'. However, our copy never names insulin resistance as the specific outcome, and it never attributes the phenomenon 'principally' to subcutaneous depots — subcutaneous appears only in the titles of cited works (refs 5, 6) and in Zaragosi et al.'s observation that activin A localizes to SVFs of omental, subcutaneous AND mesenteric depots. The depot specificity and the insulin-resistance endpoint in the citing sentence go beyond what this source states. (LLM, conf=0.72)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Adipose tissue (AT) represents a plastic organ that can undergo significant remodeling in response to metabolic demands.”
- Also stated in: § 1. The Remodeling of Adipose Tissue · boosted
“Adipose tissue (AT) is considered as a remarkably active and plastic organ with functional pleiotropism and elevated remodeling capacity [1,2].”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > Abstract
What the sources say
- Not checked yetcites [1] Cypess, 2022, Reassessing human adipose tissue, N. Engl. J. Med. source
- Supportedcites [2] De Fano, M., Bartolini, D., Tortoioli, C., Vermigli, C., Malara, M., Galli, F., and Murdolo, G. (2022). Adipose tissue plasticity in response to pathophsyiological cues: A connecting link between obesity and its associated comorbidities. Int. J. Mol. Sci., 23. source
The Abstract (p. 1) states verbatim that 'Adipose tissue (AT) is a remarkably plastic and active organ with functional pleiotropism and high remodeling capacity,' and Section 2 ('The adipose tissue: a remarkably active and plastic "organ"') reiterates the high remodeling capacity, describing remodeling that 'orchestrates nutritional adaptations in response to variations of energy balance' — i.e., in response to metabolic demands. The citing sentence is a faithful paraphrase of this framing, which the paper itself develops throughout Sections 2 and 3. (LLM, conf=0.90)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. The Remodeling of Adipose Tissue · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It has been shown that nonobese subjects with type 2 diabetes mellitus (T2D) and nondiabetic subjects with a genetic predisposition for T2D (first-degree relatives: FDR) have an unwarranted hypertrophic expansion of subcutaneous adipose tissue (SAT) [10].”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 1. The Remodeling of Adipose Tissue
What the sources say
- Partly supportedcites [10] Arner, P., Arner, E., Hmmarstedt, A., and Smith, U. (2011). Genetic predisposition for type 2 diabetes, but not for overweight/obesity, is associated with a restricted adipogenesis. PLoS ONE, 6. sourceExperimental — accuracy not yet measured
Our copy of Arner et al. 2011 fully supports the hereditary arm: the Results (Fat cell size in relation to body fat; Phenotypic characterization) and Discussion state that non-obese individuals with a genetic predisposition for T2D (recruited as first-degree relatives, Materials and Methods > Subjects) show inappropriately enlarged abdominal (subcutaneous, per Methods) fat cells with raised delta-values, i.e. unwarranted hypertrophic expansion. The other arm of the claim — nonobese subjects who actually HAVE type 2 diabetes — is not a study population of this paper: the Subjects section lists only T2D-heredity, obesity-heredity and control cohorts (164 lean, 500 overweight/obese; 166 Gothenburg FDRs), with no diabetic patients measured. The Introduction mentions adipose-cell hypertrophy in patients with Type 2 diabetes only to credit it to other works ([13], [14]) and to prior papers of theirs ([10], [11], [15]). (LLM, conf=0.78)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This provocative concept (“expandability hypothesis”) justifies in part the seeming paradox of an increased risk of IR under circumstances when body fat is both reducing (i.e., lipodystrophy) and expanding (i.e., adiposity) [4,5].”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 1. The Remodeling of Adipose Tissue
What the sources say
- Not checked yetcites [4] Danforth, 2000, Failure of adipocyte differentiation causes type II diabetes mellitus?, Nat. Genet. source
- Supportedcites [5] Sethi, 2010, Activatin’ human adipose progenitors in obesity, Diabetes source
The opening section of our copy ("Activatin' Human Adipose Progenitors in Obesity," p. 1) names the "adipose tissue expandability hypothesis" as a "seemingly counterintuitive hypothesis" and states that adipose mass accumulation per se may not be directly causative, that expansion has a limit beyond which ectopic fat deposition causes lipotoxicity and metabolic dysregulation, and then that "similar metabolic consequences may also be predicted ... when there is a paucity of adipose tissue" — i.e., the same metabolic risk at both the expanding (adiposity) and reducing (lipodystrophy/paucity) extremes, which is exactly the paradox the citing sentence attributes to it. The closing paragraph ("limitations in fat storage can lead to metabolic disorders") reinforces this. Minor wording gap: our copy frames the outcome as "metabolic dysregulation/obesity-related metabolic abnormalities" and diabetes rather than using the term "insulin resistance" explicitly, but the substance is the same. The hypothesis is discussed and relied upon in the author's own text (with reference 1, Sethi & Vidal-Puig 2007, cited as background), so this is not a mere credit-to-another-work case. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
93 more claims · 50 with their cited sources checked
Create a free account to see all 192 claims and to verify the 124 references still open.
- It may state two separate claims as one. 72
- Probably not a substantial claim. 36
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Incretin-based agents induce significant weight loss, comparable to bariatric surgery, predominantly targeting adipose tissue.”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Through these mechanisms, incretin-based medications promote body weight reduction primarily by targeting AT [6].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 5. GLP-1 and GIP Actions in Liver and Skeletal Muscle
“O’Harte et al. showed that GIP enhanced glucose transport in the mouse diaphragm [56].”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > References
“Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 8. The Fine-Tuning of GLP-1/GLP1-R and GIP/GIP-R Axis in Fat: How to Reconcile This Challenging Puzzle?
“the protective role of GLP1-R activation by promoting adipogenesis and increasing the capacity of adipose cells to store lipids, thus decreasing ectopic lipid overflow and enhancing IR.”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 6. Expression and Activity of GLP-1 Receptors in Adipose Tissue > 6.1. White Adipose Tissue and GLP-1R Expression in Adipocytes and Stroma Vascular Fraction: A Depot-Dependent Difference?
“the promotion of adipogenesis through the activation of GLP-1R enhances the capacity of visceral hypertrophic adipocytes to store lipids, thus decreasing the ectopic lipid store and improving IR”
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Furthermore, GLP-1 and exendin-4 (a GLP-1 R agonist) stimulate glycogen synthase activity and glucose metabolism in rat soleus muscle and human skeletal muscle [54].”
BackgroundSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×
“…impact on body weight [20], appetite [21], gastric emptying [22] and, moreover, some of these (liraglutide, dulaglutide, semaglutide sc) have shown a crucial cardiovascular protective effect in specific Cardiovascular Outcome Trials (CVOTs), both in subjects with T2D [23] and obesity [24].”
BackgroundSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961 · cited 1×
“It is commonly known that an increase in abdominal VAT is associated with a raised risk of cardio-metabolic issues and an increased ability to predict death [71,72].”
BackgroundDynamics of fat cell turnover in humans
Spalding, K. L., Arner, E., Westermark, P. O., Bernard, S., Buchholz, B. A., Bergmann, O., Blomqvist, L., Hoffstedt, J., Näslund, E., Britton, T., et al. (2008) · Nature · doi:10.1038/nature06902 · Cited by 2,357
Subcutaneous and visceral adipose tissue: Structural and functional differences
Ibrahim, M. M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00623.x · Cited by 2,238 · cited 1×
“It is commonly known that an increase in abdominal VAT is associated with a raised risk of cardio-metabolic issues and an increased ability to predict death [71,72].”
BackgroundSex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
Human epicardial adipose tissue is a source of inflammatory mediators
Mazurek, T., Zhang, L., Zalewski, A., Mannion, J. D., Diehl, J. T., Arafat, H., Sarov-Blat, L., O’Brien, S., Keiper, E. A., Johnson, A. G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000099542.57313.c5 · Cited by 1,966 · cited 1×
“Surprisingly, an excess of epicardial fat has been linked to IR and cardiovascular disorders, significantly influencing atherosclerosis through the paracrine release of pro-inflammatory cytokines [70].”
BackgroundAdipose tissue remodeling and obesity
Sun, K., Kusminski, C. M., & Scherer, P. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45887 · Cited by 1,941 · cited 1×
“It is theoretically possible for “healthy”, “unhealthy” or pathological processes to cause AT accrual [6].”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 1×
“Additionally, due to their insulinotropic action, incretin hormones regulate glucagon release: GIP has been found to stimulate glucagon secretion, particularly at lower glucose values [14], whereas GLP-1 suppresses glucagon release and, consequently, reduces hepatic glucose production [15].”
BackgroundGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“…impact on body weight [20], appetite [21], gastric emptying [22] and, moreover, some of these (liraglutide, dulaglutide, semaglutide sc) have shown a crucial cardiovascular protective effect in specific Cardiovascular Outcome Trials (CVOTs), both in subjects with T2D [23] and obesity [24].”
BackgroundAdipogenesis and metabolic health
Ghaben, A. L., & Scherer, P. E. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0093-z · Cited by 1,395 · cited 1×
“In fact, AT is remarkably capable of expanding to more than double its original size by hypertrophy (enlargement of the cell size) and/or hyperplasia (increase in cell number) [3].”
BackgroundReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16–18].”
BackgroundTriple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 2×
“It may also mediate the unfavorable consequences, not only of high-fat diets [112], but also of quickly assimilated or high-glycemic-index carbohydrates, a feature of highly processed foods that are commonly found in Western diets [51].”
BackgroundThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“These areas are primarily found in the brain stem (area postrema, nucleus tractus solitarii, lateral parabrachial nucleus), as well as the hypothalamus (arcuate, paraventricular, ventromedial and dor-somedial nuclei) [29,30].”
BackgroundIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · cited 1×
“…insulinotropic polypeptide (GIP) are secreted from different cells located in the gut, respectively, L cells (whose concentration increases from the lower jejunum to the ileum and then further to the colon and rectum) and K cells (primarily present in the duodenum and upper je-junum) [11,12].”
BackgroundKlöting, N., Fasshauer, M., Dietrich, A., Kovacs, P., Schön, M. R., Kern, M., Stumvoll, M., & Blüher, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00586.2009 · Cited by 856 · cited 5×
“It has been suggested that these cells reciprocally interact to induce inflammation [119].”
BackgroundInfluentialSemaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 1×
“These areas are primarily found in the brain stem (area postrema, nucleus tractus solitarii, lateral parabrachial nucleus), as well as the hypothalamus (arcuate, paraventricular, ventromedial and dor-somedial nuclei) [29,30].”
BackgroundBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“Studies on carcinogenicity in rats and mice showed a dose-and time-dependent elevated risk of medullary carcinomas, primarily because of the increased release of calcitonin and the up-regulated expression of the calcitonin gene, which led to C-cell hyperplasia [127].”
BackgroundAdipocyte inflammation is essential for healthy adipose tissue expansion and remodeling
Wernstedt Asterholm, I., Tao, C., Morley, T. S., Wang, Q. A., Delgado-Lopez, F., Wang, Z. V., & Scherer, P. E. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.005 · Cited by 668
Adipocyte Turnover: Relevance to Human Adipose Tissue Morphology
Arner, E., Westermark, P. O., Spalding, K. L., Britton, T., Rydén, M., Frisén, J., Bernard, S., & Arner, P. (2010) · Diabetes · doi:10.2337/db09-0942 · Cited by 645 · cited 1×
“…patterns appear tightly entwined: the link between obesity and adipose cell size is undoubtedly curvilinear, and as numerous elegant investigations have been demonstrated in studies [8–10], the formation of new adipocytes is triggered when the increase in adipocyte size arrives at a plateau [7].”
ResultGLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 1×
“Nevertheless, the results showed reduced or unaltered REE in both studies after treatment with GLP-1 Ras, as opposed to the first studies, where GLP-1 RAs led to a raised REE, mainly when adjusted for fat-free mass [101].”
ResultDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 1×
“Moreover, in obese mice, the administration of GLP-1 agonists reduced hepatic steatosis [48], an effect that has also been replicated in humans [47,49].”
BackgroundGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · cited 1×
“Moreover, in obese mice, the administration of GLP-1 agonists reduced hepatic steatosis [48], an effect that has also been replicated in humans [47,49].”
BackgroundT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498 · cited 1×
“Numerous bodies of evidence suggest that GLP-1 effects on hepatic glucose metabolism may be neurally mediated, even though the exact processes behind this result are as yet unknown ([45]; and references therein).”
BackgroundFailure of adipocyte differentiation causes type II diabetes mellitus?
Danforth, E. (2000) · Nature Genetics · doi:10.1038/79111 · Cited by 487 · cited 1×
“This provocative concept (“expandability hypothesis”) justifies in part the seeming paradox of an increased risk of IR under circumstances when body fat is both reducing (i.e., lipodystrophy) and expanding (i.e., adiposity) [4,5].”
BackgroundImpaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity
Hammarstedt, A., Gogg, S., Hedjazifar, S., Nerstedt, A., & Smith, U. (2018) · Physiological Reviews · doi:10.1152/physrev.00034.2017 · Cited by 462 · cited 2×
“…of resident cell types, such as immune cells, endothelial precursor cells, and (pre)adipocytes, this metabolic process is mainly brought about by combination of adipocyte hypertrophy of preexisting cells and hyperplasia (i.e., the recruitment and differentiation of new adipose precursor cells) [7].”
BackgroundResultRosenbaum, M., Hirsch, J., Gallagher, D. A., & Leibel, R. L. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.4.906 · Cited by 444 · cited 1×
“This dissonance might potentially be clarified by the fact that the first studies were carried out with the use of different methodologies and during dissimilar periods of therapy; nonetheless, it is commonly believed that REE decreases after weight reduction [102].”
BackgroundHow May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419 · cited 1×
“…some research views GIP’s action as beneficial and suggests that it could aid in the growth of healthy SAT depots, other studies claim that it may support the expansion of healthy SAT depots [109], whereas other studies consider GIP as an endogenous hormone that promotes obesity in AT [110,111].”
ResultGLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407 · cited 1×
“On the other hand, no prominent direct effect has been seen hitherto for GIP [14,28].”
BackgroundNauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407 · cited 1×
“…like tirzepatide have higher efficacy as compared with selective GLP-1 RAs as regards glycemic control and body weight, and the consequent approval for the treatment of T2D and obesity, reinvigorated interest in GIP, which in the past was thought to be without any therapeutic potential [25].”
BackgroundSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Reassessing human adipose tissue
Cypess, A. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032804 · Cited by 404 · cited 1×
“Adipose tissue (AT) is considered as a remarkably active and plastic organ with functional pleiotropism and elevated remodeling capacity [1,2].”
BackgroundNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388 · cited 1×
“…insulinotropic polypeptide (GIP) are secreted from different cells located in the gut, respectively, L cells (whose concentration increases from the lower jejunum to the ileum and then further to the colon and rectum) and K cells (primarily present in the duodenum and upper je-junum) [11,12].”
BackgroundMeier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369 · cited 1×
“Furthermore, the action of GLP-1 and GLP-1 RAs (especially short acting) on gastric and intestinal cells causes, respectively, the deceleration of gastric emptying [31] and the reduction in intestine motility [32], which both impact the absorption of nutrients.”
BackgroundReduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349 · cited 1×
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16–18].”
BackgroundGinsberg, H. N., & MacCallum, P. R. (2009) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00044.x · Cited by 331 · cited 1×
“Accordingly, numerous studies have shown that following glucose overload, IR and diabetes clearly exhibit a decrease in circulating GLP-1 [58,67].”
BackgroundGlucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320 · cited 2×
“Also, the use of DPP4-i was found to be associated with a higher risk of thyroid cancer, leading the authors to hypothesize that this association might be partly explained by increased endogenous GLP-1 levels after the inhibition of DPP-4 [132].”
BackgroundResultLee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · cited 2×
“Furthermore, GLP-1 RAs prevent resident macrophages in AT from being activated by nuclear factor-kappa B (NF-κ B) [73].”
BackgroundMeier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314 · cited 6×
“GLP-1 receptors (GLP-1R) and GIP receptors (GIP-R) are expressed in many tissues in animals and humans [14].”
BackgroundInfluentialRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289 · cited 2×
“Their presence is also found on delta and PP cells, whereas the presence of GLP-1R on these cell populations is uncertain ([14] and references therein, [26]).”
BackgroundOscillations of cyclic AMP in hormone-stimulated insulin-secreting β-cells
Dyachok, O., Isakov, Y., Sågetorp, J., & Tengholm, A. (2006) · Nature · doi:10.1038/nature04410 · Cited by 247 · cited 1×
“Transiently, the action of GLP-1R is regulated via the timing of cAMP fluctuations in beta cells, leading to prolonged rises of cAMP triggering a nuclear translocation of activated PKA [40].”
BackgroundRegional impact of adipose tissue morphology on the metabolic profile in morbid obesity
Hoffstedt, J., Arner, E., Wahrenberg, H., Andersson, D. P., Qvisth, V., Löfgren, P., Rydén, M., Thörne, A., Wirén, M., Palmér, M., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1889-3 · Cited by 246 · cited 1×
“It has been supposed that the promotion of adipogenesis through the activation of GLP-1R enhances the capacity of visceral hypertrophic adipocytes to store lipids, thus decreasing the ectopic lipid store and improving IR, as demonstrated by Hoffstedt et al. [66].”
BackgroundMonami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243 · cited 1×
“In contrast, recent meta-analyses of randomized control trials indicate the lack of signals related to the increase in the risk of pancreatic and breast cancer, in subjects treated with GLP-1 RAs either for T2D or for obesity [133].”
ResultFunctional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237
Impaired regulation of the incretin effect in patients with type 2 diabetes
Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219
Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diab.28.12.1141 · Cited by 219 · cited 2×
“However, the presence of GIP-R on fat cells was shown in cell culture, animal and human models by gene expression and functional assays [103–105].”
BackgroundInduction of Adipose Tissue Browning as a Strategy to Combat Obesity
Kuryłowicz, A., & Puzianowska-Kuźnicka, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176241 · Cited by 219
Prigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199 · cited 1×
“Human hepatic glucose production is reduced by 20–30% when GLP-1 is infused during the experimental setting with clamped insulin and glucagon concentrations [44].”
BackgroundHeppner, K. M., Kirigiti, M., Secher, A., Paulsen, S. J., Buckingham, R., Pyke, C., Knudsen, L. B., Vrang, N., & Grove, K. L. (2015) · Endocrinology · doi:10.1210/en.2014-1675 · Cited by 196 · cited 1×
“…GIP-R in other brain regions (such as the substantia nigra, hippocampus and amygdala) may be also implicated in anti-apoptotic effects, synaptic plasticity, memory, reward functions and emotional responses [33], enough to be studied in specific ongoing trials regarding neuro-degenerative disorders.”
BackgroundQuoyer, J., Longuet, C., Broca, C., Linck, N., Costes, S., Varin, E., Bockaert, J., Bertrand, G., & Dalle, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.067207 · Cited by 187 · cited 1×
“…has been reported to influence GLP1R signaling: the PKA-induced activation of ERK-1 and -2 seems to be momentary and causes its translocation to the nucleus, while GLP-1R β -arrestin-induced ERK 1/2 activation, rather than inducing translocation, preferentially acts on cytoplasmic targets [39].”
BackgroundAlves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186 · cited 1×
“The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) clinical trial and a meta-analysis of 12 clinical trials with liraglutide both reported a non-statistically significant increase in thyroid cancers [128,129].”
BackgroundKrasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186 · cited 1×
“Moreover, GLP-1 RAs have an anti-inflammatory effect on endothelial vascular cells through a number of molecular mechanisms, including the activation of adenosine monophosphate-activated protein kinase (AMPK) [75].”
BackgroundAsmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010) · Diabetes · doi:10.2337/db10-0098 · Cited by 184 · cited 2×
“Additional research verified that GIP did not alter energy metabolism or appetite, nor did it alter TAG clearance in the absence of insulin when compared with saline infusion of lipid emulsions [114].”
BackgroundKim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040156 · Cited by 182 · cited 1×
“Notwithstanding, significant general GIP overexpression prevents obesity and lowers inflammatory markers in mice [123].”
BackgroundReappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · cited 1×
“The latter have shown a significant impact on body weight [20], appetite [21], gastric emptying [22] and, moreover, some of these (liraglutide, dulaglutide, semaglutide sc) have shown a crucial cardiovascular protective effect in specific Cardiovascular Outcome Trials (CVOTs), both in subjects with…”
BackgroundIqbal, J., Wu, H., Hu, N., Zhou, Y., Li, L., Xiao, F., Wang, T., Jiang, H., Xu, S., Huang, B., et al. (2022) · Obesity Reviews · doi:10.1111/obr.13435 · Cited by 179 · cited 1×
“The latter have shown a significant impact on body weight [20], appetite [21], gastric emptying [22] and, moreover, some of these (liraglutide, dulaglutide, semaglutide sc) have shown a crucial cardiovascular protective effect in specific Cardiovascular Outcome Trials (CVOTs), both in subjects with…”
BackgroundVendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1070 · Cited by 173 · cited 4×
“Since the 1990s, reports have indicated that isolated mouse and human adipocytes contain GLP1-R ([58], and references therein).”
BackgroundInfluentialMenstrual cycle and voluntary food intake
Gong, E. J., Garrel, D., & Calloway, D. H. (1989) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/49.2.252 · Cited by 163 · cited 1×
“Studies on humans suggest that food consumption tends to be lower during the follicular phase and the periovulatory period, but higher during the luteal phase, demonstrating an opposite correlation with estrogen levels [92].”
BackgroundRegulation of insulin gene transcription by ERK1 and ERK2 in pancreatic β cells
Khoo, S., Griffen, S. C., Xia, Y., Baer, R. J., German, M. S., & Cobb, M. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301198200 · Cited by 163 · cited 1×
“Receptor compartmentalization may limit the action of downstream signaling partners [38].”
BackgroundGLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1
Xu, F., Lin, B., Zheng, X., Chen, Z., Cao, H., Xu, H., Liang, H., & Weng, J. (2016) · Diabetologia · doi:10.1007/s00125-016-3896-5 · Cited by 157 · cited 1×
“Recent research characterized the incretin system in fat tissue, and one intriguing finding was that GLP-1R appears to play a significant role in energy metabolism by directly promoting brown AT (BAT) and mitochondrial bioenergetics remodeling [94].”
BackgroundWang, L., Wang, W., Kaelber, D. C., Xu, R., & Berger, N. A. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5573 · Cited by 150 · cited 1×
“…cohort study including more than one million drug-naïve patients with T2D found that, during a 15-year follow up period, treatment with GLP-1 RAs was associated with a decreased risk of colorectal cancer compared with insulin, metformin, SGLT2-i, sulfonylureas and thiazolidinediones [134].”
BackgroundRegulation of Adipocyte Formation by GLP-1/GLP-1R Signaling
Challa, T. D., Beaton, N., Arnold, M., Rudofsky, G., Langhans, W., & Wolfrum, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.310342 · Cited by 149 · cited 2×
“According to experimental research, GLP-1 can certainly cause both lipogenic and lipolytic effects in a dose-dependent manner, with lipogenic action predominating at picomolar concentrations and lipolytic action at nanomolar doses [59–63].”
BackgroundArner, P., Arner, E., Hammarstedt, A., & Smith, U. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018284 · Cited by 146 · cited 2×
“It has been shown that nonobese subjects with type 2 diabetes mellitus (T2D) and nondiabetic subjects with a genetic predisposition for T2D (first-degree relatives: FDR) have an unwarranted hypertrophic expansion of subcutaneous adipose tissue (SAT) [10].”
BackgroundResultRentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140 · cited 3×
“Obesity and T2D are characterized by sexual dimorphism, which appears to be an important determinant of presentation, diagnosis, disease progression and complications, and, therefore, may be important for individual treatment approaches ([76–78]; and references therein).”
BackgroundSong, D. H., Getty–Kaushik, L., Tseng, E., Simon, J., Corkey, B. E., & Wolfe, M. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.005 · Cited by 137 · cited 2×
“Furthermore, GIP-R expression increases with the differentiation of adipocytes [107].”
BackgroundNauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137 · cited 1×
“This is on basis of the “incretin effect”, defined as a two-to-three-fold higher insulin secretory response to oral as compared to intravenous glucose administration, in a glucose-dependent manner and due to the direct action of GLP-1 and GIP on beta-cells [13].”
BackgroundGlucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification
Getty‐Kaushik, L., Song, D. H., Boylan, M. O., Corkey, B. E., & Wolfe, M. M. (2006) · Obesity · doi:10.1038/oby.2006.129 · Cited by 134
Ehses, J. A., Pelech, S. L., Pederson, R. A., & McIntosh, C. H. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205055200 · Cited by 133 · cited 1×
“Studies performed in cultured cells have shown that GIP can influence the activity of all known kinases of the ERK-1 and -2 module, including Mek1/2, Raf-1 and p90 RSK [42].”
BackgroundWeiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s277676 · Cited by 126
Marzook, A., Tomas, A., & Jones, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.678055 · Cited by 121 · cited 1×
“Insulin release from pancreatic beta cells is, by far, the most well studied mechanism of intracellular signaling by GLP-1R ([37], and references therein).”
BackgroundEffect of GLP-1 on lipid metabolism in human adipocytes
Villanueva-Peñacarrillo, M. L., Márquez, L., González, N., Díaz-Miguel*, M., & Valverde, I. (2001) · Hormone and Metabolic Research · doi:10.1055/s-2001-12428 · Cited by 113
Roche, M. M., & Wang, P. P. (2013) · Diabetes Care · doi:10.2337/dc12-1272 · Cited by 113 · cited 1×
“On the other hand, females with T2D exhibit a worse prognosis than men showing higher cardiovascular disease (CVD) risk and all-cause and CVD-related mortality [79,81].”
BackgroundDisruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance
Ceperuelo-Mallafré, V., Duran, X., Pachón, G., Roche, K., Garrido-Sánchez, L., Vilarrasa, N., Tinahones, F. J., Vicente, V., Pujol, J., Vendrell, J., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3350 · Cited by 112
Allostery and biased agonism at class B G protein-coupled receptors
Wootten, D., Miller, L. J., Koole, C., Christopoulos, A., & Sexton, P. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00049 · Cited by 112 · cited 1×
“As far as GIP is concerned, after binding its receptor on beta cells, GIP transduces its biological effects by increasing in cAMP and intracytoplasmic Ca 2+ levels, in addition to the activation of PI3K, AKT, PKA, p38 MAP kinases and phospholipase A2 [41].”
BackgroundHuman epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes
Iacobellis, G., Camarena, V., Sant, D., & Wang, G. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-109563 · Cited by 112 · cited 1×
“The epicardial AT, the heart’s counterpart in visceral fat, was found to express GLP-1R [69].”
BackgroundMusso, G., Gambino, R., Pacini, G., De Michieli, F., & Cassader, M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26720 · Cited by 107 · cited 2×
“Nonetheless, there seems to be a clear correlation between the rate of hepatic steatosis and the GIP response [51].”
BackgroundGut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126107 · Cited by 106 · cited 1×
“In fact, it has been suggested that, in obesity, elevated circulating GIP levels lead to the activation of EPAC/Raf1 signaling and this is an important condition for inducing neural leptin resistance [43].”
BackgroundSex and estrogens alter the action of glucagon-like peptide-1 on reward
Richard, J. E., Anderberg, R. H., López-Ferreras, L., Olandersson, K., & Skibicka, K. P. (2016) · Biology of Sex Differences · doi:10.1186/s13293-016-0059-9 · Cited by 102 · cited 1×
“Finally, referring to sexual dimorphism in weight loss from another point of view, it has been highlighted that estrogen signaling plays a crucial role in the food-reward aspect of food seeking induced by GLP-1 RAs [91].”
BackgroundGLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway
Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., & Mi, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119300 · Cited by 101 · cited 1×
“All things considered, these results point to the possibility that GLP-1 increases physical endurance by causing skeletal muscle remodeling [55].”
BackgroundEffects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes
Hauner, H., Glatting, G., Kaminska, D., & Pfeiffer, E. F. (1988) · Annals of Nutrition and Metabolism · doi:10.1159/000177467 · Cited by 98 · cited 1×
“However, the presence of GIP-R on fat cells was shown in cell culture, animal and human models by gene expression and functional assays [103–105].”
BackgroundGallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13086 · Cited by 98 · cited 1×
“In a retrospective pool analysis of subjects with T2D receiving exenatide (twice daily) or dulaglutide (once weekly), a reduction in HbA1c occurred irrespective of sex [85].”
BackgroundLink between GIP and osteopontin in adipose tissue and insulin resistance
Ahlqvist, E., Osmark, P., Kuulasmaa, T., Pilgaard, K., Omar, B., Brøns, C., Kotova, O., Zetterqvist, A. V., Stančáková, A., Jonsson, A., et al. (2013) · Diabetes · doi:10.2337/db12-0976 · Cited by 96 · cited 2×
“Furthermore, increased levels of osteopontin (which is involved in T-cell activation and di ff erentiation as well as macrophage activation) and a higher risk of CVD were linked to GIP-R polymorphisms and circulating levels of GIP [125].”
BackgroundGögebakan, Ö., Osterhoff, M. A., Schüler, R., Pivovarova, O., Kruse, M., Seltmann, A.-C., Mosig, A. S., Rudovich, N., Nauck, M., & Pfeiffer, A. F. H. (2015) · Diabetologia · doi:10.1007/s00125-015-3618-4 · Cited by 95 · cited 4×
“Co-cultures of human fat cells and human macrophages showed the augmented release of monocyte chemoattractant protein-1 (MCP-1), a chemokine implicated in the migration and infiltration of monocytes/macrophages, in the presence of GIP [116].”
BackgroundInfluentialNauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
Yuan, P., Ma, D., Gao, X., Wang, J., Li, R., Liu, Z., Wang, T., Wang, S., Liu, J., & Liu, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01257 · Cited by 93 · cited 1×
“Furthermore, GLP-1R may also be found in the corpus cavernosum, supporting the benefits of GLP-1 RAs for erectile function [36].”
BackgroundLipolytic action of glucagon-like peptides in isolated rat adipocytes
Ruiz-Grande, C., Alarcón, C., Mérida, E., & Valverde, I. (1992) · Peptides · doi:10.1016/0196-9781(92)90134-o · Cited by 89
Timper, K., Grisouard, J., Sauter, N. S., Herzog-Radimerski, T., Dembinski, K., Peterli, R., Frey, D. M., Zulewski, H., Keller, U., Müller, B., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00100.2012 · Cited by 88 · cited 2×
“In contrast, other in vitro research highlighted that GIP also supports lipolysis [108].”
BackgroundResultGlucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85 · cited 1×
“…some research views GIP’s action as beneficial and suggests that it could aid in the growth of healthy SAT depots, other studies claim that it may support the expansion of healthy SAT depots [109], whereas other studies consider GIP as an endogenous hormone that promotes obesity in AT [110,111].”
ResultGlucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes
YANG, J., REN, J., SONG, J., LIU, F., WU, C., WANG, X., GONG, L., LI, W., XIAO, F., YAN, F., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1350 · Cited by 84 · cited 2×
“Accordingly, GLP-1 and exendin-4 treatment enhanced the differentiation of murine 3T3-L1 adipocyte precursors [64].”
BackgroundThazhath, S. S., Marathe, C. S., Wu, T., Chang, J., Khoo, J., Kuo, P., Checklin, H. L., Bound, M. J., Rigda, R. S., Crouch, B., et al. (2016) · Diabetes · doi:10.2337/db15-0893 · Cited by 83 · cited 1×
“Furthermore, the action of GLP-1 and GLP-1 RAs (especially short acting) on gastric and intestinal cells causes, respectively, the deceleration of gastric emptying [31] and the reduction in intestine motility [32], which both impact the absorption of nutrients.”
Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
El Bekay, R., Coín‐Aragüez, L., Fernández‐García, D., Oliva‐Olivera, W., Bernal‐López, R., Clemente‐Postigo, M., Delgado‐Lista, J., Diaz‐Ruiz, A., Guzman‐Ruiz, R., Vázquez‐Martínez, R., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13481 · Cited by 78
GLP-1 amplifies insulin signaling by up-regulation of IRβ, IRS-1 and Glut4 in 3T3-L1 adipocytes
Gao, H., Wang, X., Zhang, Z., Yang, Y., Yang, J., Li, X., & Ning, G. (2007) · Endocrine · doi:10.1007/s12020-007-9011-4 · Cited by 77 · cited 1×
“This enhanced intracellular lipid storage and insulin-mediated glucose uptake promoting intracellular lipid storage and insulin-mediated glucose uptake via the up-regulation of GLUT4 expression and phosphorylation of the insulin receptor in adipose cells [65].”
BackgroundThondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170208 · Cited by 77 · cited 1×
“GIPR-/- mice exhibit considerably lower expression of the inflammatory adipokine IL-6, which is regulated by the suppression of inflammatory cytokine signaling (SOCS3), indicating that GIP may play a role in inflammatory change within a fatty liver ([50]; and references therein).”
BackgroundSex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity
Pasquali, R., Vicennati, V, Gambineri, A., & Pagotto, U. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.129 · Cited by 74 · cited 1×
“Yet, differences in adipose tissue distribution may well explain such a difference since abdominal obesity, a hallmark of the metabolically unhealthy obese phenotype, is present in almost 70% of women diagnosed with T2D as compared to approximately 40% of men [80].”
BackgroundHigh glycemic index metabolic damage – a pivotal role of GIP and GLP-1
Pfeiffer, A. F. H., & Keyhani-Nejad, F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.03.003 · Cited by 74 · cited 1×
“In this regard, it has been shown that acarbose, an α -glucosidase inhibitor, lowers GIP release and delays the absorption of glucose, which results in a decrease in the amount of fat in the liver [52,53].”
BackgroundZhang, E., Xu, F., Liang, H., Yan, J., Xu, H., Li, Z., Wen, X., & Weng, J. (2015) · American Journal of Reproductive Immunology · doi:10.1111/aji.12420 · Cited by 73 · cited 1×
“It has been reported that GLP-1R is present in the testis [34], and it has been shown that GLP-1 RAs can lower testicular inflammation and improve the quality of sperm in obese mice [35].”
BackgroundThondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00347.2016 · Cited by 71 · cited 1×
“Such an interest also stems from the higher effect on glycemic control and weigh loss showed with GIP/GLP-1 co-agonists like tirzepatide [135], as well as the intriguing effects of retatrutide, the first GIP/GLP-1/GCGR (glucagon receptor) co-agonist [136].”
BackgroundGIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
Mantelmacher, F. D., Zvibel, I., Cohen, K., Epshtein, A., Pasmanik-Chor, M., Vogl, T., Kuperman, Y., Weiss, S., Drucker, D. J., Varol, C., et al. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0001-z · Cited by 70 · cited 1×
“On the other hand, the targeted deletion of GIP in myeloid immune cells resulted in increased inflammatory responses, suggesting that endogenous GIP may have an anti-inflammatory role [121].”
BackgroundGlucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67 · cited 1×
“These findings undoubtedly show how endogenous GIP functions, but they might not provide useful information about a pharmacological agonist or antagonists [113].”
BackgroundQuan, H., Zhang, H., Wei, W., & Fang, T. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.01.013 · Cited by 65 · cited 1×
“On the other hand, other studies highlighted a sex-specific response to GLP-1 Ras, indicating that females exhibit a wider reduction in HbA1c levels when compared with males after treatment with exenatide plus metformin [86].”
BackgroundLiraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0410-7 · Cited by 64 · cited 1×
“The results of pharmacokinetic analysis revealed that women had a 32% higher liraglutide exposure than men did at similar weights, establishing the female sex as an independent predictor of successful weight loss [89].”
BackgroundSeghieri, G., Anichini, Cosimi, S., Carlo, D., Bellis, D., Franconi, Orsini, P., & Baccetti (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s42729 · Cited by 63 · cited 1×
“Lastly, further research suggested a superior response in males to treatment with GLP-1 RAs [88].”
Glucagon‐like peptide‐1 receptor is expressed in human and rodent testis
Caltabiano, R., Condorelli, D. F., Panza, S., Boitani, C., Musso, N., Ježek, D., Memeo, L., Colarossi, L., Rago, V., Mularoni, V., et al. (2020) · Andrology · doi:10.1111/andr.12871 · Cited by 63 · cited 1×
“It has been reported that GLP-1R is present in the testis [34], and it has been shown that GLP-1 RAs can lower testicular inflammation and improve the quality of sperm in obese mice [35].”
BackgroundEffect of gender on treatment outcomes in type 2 diabetes mellitus
McGill, J. B., Vlajnic, A., Knutsen, P. G., Recklein, C., Rimler, M., & Fisher, S. J. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.10.001 · Cited by 61 · cited 1×
“For example, studies in the literature showed that men treated with insulin glargine or dapagliflozin, a sodium glucose cotransporter 2 inhibitor (SGLT2-i), were more likely to achieve better glycemic target in comparison to women [82,83].”
MethodAsmar, M., Simonsen, L., Asmar, A., Holst, J. J., Dela, F., & Bülow, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1933 · Cited by 61 · cited 1×
“Accordingly, other research highlighted the insulin-dependent effects of GIP on adipose tissue blood flow and metabolism, through insulin inhibition mediated by the administration of somatostatin [115].”
BackgroundO'Harte, F., Gray, A., & Flatt, P. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1560237 · Cited by 60
van Eyk, H. J., Paiman, E. H. M., Bizino, M. B., IJzermans, S. L., Kleiburg, F., Boers, T. G. W., Rappel, E. J., Burakiewicz, J., Kan, H. E., Smit, J. W. A., et al. (2020) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.12.005 · Cited by 54
Janssen, L. G. M., Nahon, K. J., Bracké, K. F. M., van den Broek, D., Smit, R., Sardjoe Mishre, A. S. D., Koorneef, L. L., Martinez-Tellez, B., Burakiewicz, J., Kan, H. E., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154167 · Cited by 54
GLP-1 (7-36) amide: Effects on glucose transport and metabolism in rat adipose tissue
Perea, A., Viñambres, C., Clemente, F., Villanueva-Peñacarrillo, M., & Valverde, I. (1997) · Hormone and Metabolic Research · doi:10.1055/s-2007-979068 · Cited by 53
Nie, Y., Ma, R. C., Chan, J. C. N., Xu, H., & Xu, G. (2012) · The FASEB Journal · doi:10.1096/fj.11-196782 · Cited by 53 · cited 1×
“Furthermore, the overexpression of GIP-R in 3T3-L1 cells enhanced an increase in Jun N-terminal kinase (JNK), a mitogen-activated protein kinase (MAPK), and IR [118].”
BackgroundEjarque, M., Guerrero-Pérez, F., de la Morena, N., Casajoana, A., Virgili, N., López-Urdiales, R., Maymó-Masip, E., Pujol Gebelli, J., Garcia Ruiz de Gordejuela, A., Perez-Maraver, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42770-1 · Cited by 53
Fano, M. D., Bartolini, D., Tortoioli, C., Vermigli, C., Malara, M., Galli, F., & Murdolo, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105511 · Cited by 47 · cited 5×
“Adipose tissue (AT) is considered as a remarkably active and plastic organ with functional pleiotropism and elevated remodeling capacity [1,2].”
BackgroundInfluentialSelf-citationShen, W.-R., Kimura, K., Ishida, M., Sugisawa, H., Kishikawa, A., Shima, K., Ogawa, S., Qi, J., & Kitaura, H. (2018) · Journal of Immunology Research · doi:10.1155/2018/5783639 · Cited by 45 · cited 1×
“For instance, exendin-4 prevents macrophages from expressing TNF-α in response to LPS [74].”
BackgroundGutierrez, A. D., Gao, Z., Hamidi, V., Zhu, L., Saint Andre, K. B., Riggs, K., Ruscheinsky, M., Wang, H., Yu, Y., Miller, C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100813 · Cited by 44
De Fano, M., Bartolini, D., Tortoioli, C., Vermigli, C., Malara, M., Galli, F., & Murdolo, G. (2022) · doi:10.20944/preprints202204.0011.v1 · Cited by 41
Self-citationHropot, T., Herman, R., Janez, A., Lezaic, L., & Jensterle, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108592 · Cited by 39 · cited 2×
“Preclinical research showed that the main mechanism by which GLP-1 causes weight loss is not only by decreasing appetite and hunger but also by increasing energy expenditure, most likely by means of BAT thermogenesis [95].”
BackgroundHan, E., Kim, A., Lee, S. J., Kim, J.-Y., Kim, J. H., Lee, W. J., & Lee, B.-W. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0470-9 · Cited by 35 · cited 1×
“For example, studies in the literature showed that men treated with insulin glargine or dapagliflozin, a sodium glucose cotransporter 2 inhibitor (SGLT2-i), were more likely to achieve better glycemic target in comparison to women [82,83].”
MethodExenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study
Liang, C., Bertoia, M. L., Ding, Y., Clifford, C. R., Qiao, Q., Gagne, J. J., & Dore, D. D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13597 · Cited by 35 · cited 1×
“Furthermore, two observational studies, as well as a study based on two U.S. administrative databases did not highlight a significant increased risk of thyroid cancer with exenatide [130,131].”
BackgroundOliveira, F. C. B., Bauer, E. J., Ribeiro, C. M., Pereira, S. A., Beserra, B. T. S., Wajner, S. M., Maia, A. L., Neves, F. A. R., Coelho, M. S., & Amato, A. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.803363 · Cited by 30
Liu, F., Yang, Q., Zhang, H., Zhang, Y., Yang, G., Ban, B., Li, Y., & Zhang, M. (2022) · PLOS ONE · doi:10.1371/journal.pone.0270899 · Cited by 30 · cited 2×
“Mounting evidence indicates that GLP-1 RA treatment leads to a comparable absolute and higher-percentage decrease in VAT in comparison with SAT, implying that GLP-1 RAs may trigger other pathways that calorie restriction does not [93].”
BackgroundResultDore, D. D., Seeger, J. D., & Chan, K. A. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098612446473 · Cited by 28 · cited 1×
“Furthermore, two observational studies, as well as a study based on two U.S. administrative databases did not highlight a significant increased risk of thyroid cancer with exenatide [130,131].”
BackgroundMantelmacher, F. D., Fishman, S., Cohen, K., Pasmanik Chor, M., Yamada, Y., Zvibel, I., & Varol, C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601441 · Cited by 27 · cited 1×
“The differences could be attributed to the different roles that GIP plays in the development of immune cells with respect to the myeloid compartment [122] and in an AT milieu where it promotes monocyte differentiation into more M1 or less M2 inflammatory macrophage phenotypes [116,119].”
BackgroundIrwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27 · cited 1×
“…some research views GIP’s action as beneficial and suggests that it could aid in the growth of healthy SAT depots, other studies claim that it may support the expansion of healthy SAT depots [109], whereas other studies consider GIP as an endogenous hormone that promotes obesity in AT [110,111].”
ResultActivatin’ human adipose progenitors in obesity
Sethi, J. K. (2010) · Diabetes · doi:10.2337/db10-0923 · Cited by 25 · cited 1×
“This provocative concept (“expandability hypothesis”) justifies in part the seeming paradox of an increased risk of IR under circumstances when body fat is both reducing (i.e., lipodystrophy) and expanding (i.e., adiposity) [4,5].”
BackgroundCampesi, I., Seghieri, G., & Franconi, F. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.06.007 · Cited by 25 · cited 1×
“On the contrary, metformin appears to exhibit similar glycemic efficacy in both sexes [84].”
BackgroundDurden, E., Lenhart, G., Lopez-Gonzalez, L., Hammer, M., & Langer, J. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2015.1131703 · Cited by 23 · cited 1×
“Analogous conclusions were also reported in another analysis examining the efficacy of liraglutide, which showed that, when stratified by age, women showed a greater reduction in HbA1c values in the 18–64 age group, whereas in the over 65 age group, predominance in men was reported [87].”
ResultPro-inflammatory gene expression profile in obese adults with high plasma GIP levels
Góralska, J., Raźny, U., Polus, A., Stancel-Możwiłło, J., Chojnacka, M., Gruca, A., Zdzienicka, A., Dembińska-Kieć, A., Kieć-Wilk, B., Solnica, B., et al. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.305 · Cited by 22 · cited 1×
“In vivo studies on humans have demonstrated that the administration of GIP boosts the expression of chemokines like MCP-1 and cytokines like IL-6 [116,124].”
BackgroundSnook, L. A., Nelson, E. M., Dyck, D. J., Wright, D. C., & Holloway, G. P. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00003.2015 · Cited by 17 · cited 1×
“Also, GIP seems to promote skeletal muscle’s absorption of glucose in murine experimental models, both in the resting state and following insulin stimulation, in a PI3K-dependent manner [57].”
BackgroundRudovich, N. N., Weickert, M. O., Machann, J., & Pfeiffer, A. F. H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.004 · Cited by 16 · cited 1×
“In this regard, it has been shown that acarbose, an α -glucosidase inhibitor, lowers GIP release and delays the absorption of glucose, which results in a decrease in the amount of fat in the liver [52,53].”
BackgroundReal-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists
Piccini, S., Favacchio, G., Morenghi, E., Mazziotti, G., A. Lania, A. G., & Mirani, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111689 · Cited by 15 · cited 1×
“Obesity and T2D are characterized by sexual dimorphism, which appears to be an important determinant of presentation, diagnosis, disease progression and complications, and, therefore, may be important for individual treatment approaches ([76–78]; and references therein).”
BackgroundGender-Difference in Response to Treatment with Liraglutide 3.0 mg
Milani, I., Guarisco, G., Chinucci, M., Gaita, C., Leonetti, F., & Capoccia, D. (2024) · doi:10.20944/preprints202405.0568.v1 · Cited by 11
Sex-Differences in Response to Treatment with Liraglutide 3.0 mg
(2024) · doi:10.3390/jcm13123369 · Cited by 11
Kittah, E., Camilleri, M., Jensen, M. D., & Vella, A. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2020.0049 · Cited by 5 · cited 1×
“The latter have shown a significant impact on body weight [20], appetite [21], gastric emptying [22] and, moreover, some of these (liraglutide, dulaglutide, semaglutide sc) have shown a crucial cardiovascular protective effect in specific Cardiovascular Outcome Trials (CVOTs), both in subjects with…”
Background
Research works printed but not linked: 1
- Finan, 2016, Reapprisal of GIP pharmacology for metabolic disease, Trends Endocrinol. Metab., 22, 359
Cited by
Spotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 102
“…important, rendering any incapacity to engage new adipose cells to store excess lipids in the SAT as a preamble to the hypertrophic (unhealthy) growth of WAT, which is further characterized by an accrual infiltration of macrophages, extensive fibrosis, limited angiogenesis and ongoing hypoxia [63].”
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“The energy-dense nature of fat makes it an efficient means of storing excess energy intake and thus the body favors fat for keeping energy in reserve [91,92].”
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“Through these mechanisms, incretin-based medications promote body weight reduction primarily by targeting AT [6].”
Relationship between hepatic lipid accumulation and type 2 diabetes mellitus
Wang, Z., Zan, W., Fan, Z., & Wang, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118723 · Cited by 8
Metadata
- Authors
- De Fano, M., Malara, M., Vermigli, C., & Murdolo, G.
- Affiliations
- Complex Structure of Endocrinology and Metabolism, Department of Medicine, Azienda Ospedaliera Santa Maria Misericordia, Ospedale di Perugia, 06081 Perugia, Italy
- Azienda Ospedaliera di Perugia (IT)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-08-08
- Volume
- 25
- Issue
- 16
- Pages
- 8650
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11354636
- OpenAlex
- W4401412316
- Semantic Scholar
- a274b0ccdc198095a25a52b5310ccb7a682841da
- Cited by
- 17
- References
- 138
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 1
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- adipose tissue, incretin system, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, insulin resistance, obesity, type 2 diabetes, adipose tissue remodeling, adipogenesis, fat deposition, glucose metabolism, adipose tissue inflammation, brown adipose tissue, white adipose tissue, GLP-1 receptor agonists, GIP receptor agonist, energy balance
- MeSH terms
- Adipose Tissue, Animals, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Insulin Resistance, Obesity, Signal Transduction, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.